Brazil's RedeRio to hone key techs policy:
This article was originally published in Clinica
Executive Summary
RedeRio, an R&D network centred in Rio de Janeiro state, is Brazil's latest initiative to hone policy in key areas of medtech use. The network comprises leading R&D institutes and hospitals in the areas of orthopaedics (INTO), cardiology (INCL), cancer (INCA) and infant-maternal care (such as Hospital de Ipanema). Its first task will be to "assess the potential of the installations and equipment of the hospitals and institutes involved", said the health ministry. RedeRio's input will be used to support policy affecting the national delivery of so-called mid- to high-complexity care, currently worth an estimated R$17bn (US$7.9m) of the R$22bn budgeted for primary care. Cardiology high-complexity care alone has a R$800m budget.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.